Povorcitinib is a selective oral small-molecule JAK1 Inhibitor, with the potential to provide a new treatment option for patients suffering from autoimmune and inflammatory dermatologic diseases On 28 August, Dermavon obtained IND approval for non-segmental vitiligo and moderate to severe hidradenitis suppurativa in China, and is actively preparing for initiating the relevant clinical trials Povorcitinib will synergize with Dermavon’s commercialized innovative drug ILUMETRI, exclusive drug Hirudoid and the innovative drug under development ruxolitinib phosphate cream, etc. China Medical System Holdings Limited (“CMS”or the “Group” ) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details) together with its subsidiaries, received the drug clinical trial approval notice […]
Learn More
On July 18, 2025, at “The 4th International Green Zero-Carbon Festival & 2025 ESG Leadership Summit” held in Shanghai, China Medical System Holdings Limited (“CMS” or “the Group”) was honored with the “2025 ESG Exemplary Enterprise Award”. This award recognizes enterprises demonstrating systematic and pioneering practices across environmental, social, and governance dimensions. With its clear ESG strategy framework, quantifiable results, and continuous improvement mechanism, CMS has once again been highly recognized by authoritative institutions and the industry. Source: International Green Zero-Carbon Festival Official Website With the theme of “Advancing Green Development, Toward Zero-Carbon Future”, the summit brought together over 200 enterprises and more than 100 industry leaders to discuss the industrial opportunities and transformation pathways under the dual carbon goal. This award is a full recognition of CMS’s long-term commitment to ESG values and innovation-driven sustainable development. CMS has fully integrated the United Nations Sustainable Development Goals (SDGs) into the Group’s strategy, using top-level design to drive […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
